ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

CLC Calculus Vct Plc

60.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Calculus Vct Plc LSE:CLC London Ordinary Share GB00BYQPF348 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 60.00 50.00 70.00 60.00 60.00 60.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Investment Advice 1.53M 648k 0.0105 57.14 37.04M

Calculus VCT PLC Half-year Report (2807D)

18/10/2022 11:46am

UK Regulatory


Calculus Vct (LSE:CLC)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more Calculus Vct Charts.

TIDMCLC

RNS Number : 2807D

Calculus VCT PLC

18 October 2022

Calculus VCT Plc (the 'Company')

Interim results for the six months ended 31 August 2022 (unaudited)

For the full half yearly unaudited financial report, please refer to the Investor Information section on https://www.calculuscapital.com/calculus-vct/

 
 Financial Highlights        6 Months to       6 Months to     12 Months to 
                            31 August 2022    31 August 2021    28 February 
                                                                   2022 
========================  ================  ================  ============= 
 Dividends paid 
  per new Ordinary 
  share                         3.06p             3.02p           3.02p 
                          ----------------  ----------------  ------------- 
 Total return per 
  new Ordinary share[1]         0.38p             0.54p           4.83p 
                          ----------------  ----------------  ------------- 
 Net asset value 
  per new Ordinary 
  share                        64.91p            64.01p           67.90p 
                          ----------------  ----------------  ------------- 
 

As expected, following the dividend of 3.06 pence per share paid in July 2022, the NAV was adjusted by the same margin. However, some positive performance in the qualifying portfolio meant that there was some uplift to the NAV to 64.91 pence per share at the reporting date.

Total return by shareholder cohort

 
 Investors by calendar year     Issue price (p)*     NAV at     Cumulative   Total return**      Total return 
                                                    31 August    dividends                     on net investment 
                                                    2022 (p)     paid (p)                             *** 
 2016 subscription                         102.7        64.91        20.93       0.84x              1.19x 
 2017 subscription                          95.7        64.91        16.33       0.85x              1.21x 
 2018 subscription                          84.7        64.91        12.68       0.92x              1.31x 
 2019 subscription                          76.3        64.91        11.34       1.00x              1.43x 
 2020 subscription                          65.2        64.91         7.21       1.11x              1.58x 
 2021 subscription                          65.4        64.91         6.08       1.08x              1.55x 
 2022 subscription (current)                65.7        64.91         4.18       1.05x              1.50x 
 
   *     Weighted average in respect of each year 

** Total Return is equal to the sum of NAV at 31 August 2022 and cumulative dividends received, divided by the average issue price

*** Total Return on net investment is equal to the sum of NAV at 31 August 2022 and cumulative dividends received, divided by the average issue price less 30% tax relief

CHAIRMAN'S UPDATE

I am pleased to present your Company's results for the 6 months to 31 August 2022.

Performance summary

The war in Ukraine and resultant energy crisis have dominated the news in the six months to 31 August 2022. The portfolio has managed to gain value in the period despite these challenges, in part because the Company has few investments in the most 'at risk' sectors such as industrials and manufacturing.

The Company is pleased to announce the successful exit of Park Street Shipping in the period. In October 2021, Park Street Shipping sold its only asset, the MV Nordic London - a 2010 South Korean built, 35,000 deadweight Handysize ship, providing an overall return of 1.8x. The sale of the ship was the initial step of the exit process. In order to distribute the proceeds, the company entered Member Voluntary Liquidation on 1st April 2022 and on 5 August 2022, shareholders including Calculus VCT received 92% of the proceeds with the remainder being held by the liquidator until the liquidation has been completed.

Despite the ongoing economic challenges, the Board is pleased with the performance of the Company's portfolio and the positive uplifts in the valuations of some portfolio companies. The most significant movement in the qualifying portfolio on the upside was Wazoku which increased the NAV by GBP0.3m. The company has shown strong growth and in September 2022 raised GBP8.3m to develop its software and strengthen its team.

Another strong performer has been Oxford Biotherapeutics ("OBT") which has added GBP0.3m of value to the NAV in the period to 31 August 2022. In June 2022, the company announced a multi-year collaboration with Immunogen, receiving an upfront payment and is eligible to receive milestone payments and tiered royalties.

Home Team Content, a UK-based independent production company enjoyed an uplift in share value since February 2022, improving the NAV by GBP0.2m. The company has been making strong progress on its slate and has a range of film and TV projects at the pre-production stage.

The AIM quoted holdings have been affected by the economic climate, collectively losing GBP0.6m of value from the NAV since the year end. It is our view that this value will be regained when the global economic and political situation stabilises and markets can recover.

Other than the quoted holdings, the only portfolio company to lose value in the period was Arcis Biotechnology Holdings. The company has been facing trading issues for some time and went into administration in August 2022.

In the period to 31 August 2022, four new investments and four follow-on investments were made on behalf of the qualifying portfolio:

New Investments

 
 Date of        Name of Investment         Sector                    Amount      Percentage        Percentage 
  Investment                                                  of Investment    of ownership      of ownership 
                                                                                     by VCT        controlled 
                                                                                               by the Manager 
=============  =========================  ===============  ================  ==============  ================ 
                Destiny Pharma 
 March 2022      PLC                       Biotech               GBP500,000            1.4%              1.4% 
=============  =========================  ===============  ================  ==============  ================ 
                Riff Raff Entertainment 
 June 2022       Limited                   Entertainment         GBP424,000            9.3%             22.0% 
=============  =========================  ===============  ================  ==============  ================ 
                Notify Technology 
 June 2022       Limited                   Technology            GBP628,100            8.7%             25.8% 
=============  =========================  ===============  ================  ==============  ================ 
 August 2022    Optalitix Limited          Technology          GBP1,065,000           10.6%             14.3% 
=============  =========================  ===============  ================  ==============  ================ 
 

Follow-on Investments

 
 Date of        Name of Investment       Sector                   Amount      Percentage        Percentage 
  Investment                                               of Investment    of ownership      of ownership 
                                                                                  by VCT        controlled 
                                                                                            by the Manager 
=============  =======================  ==============  ================  ==============  ================ 
                Arcis Biotechnology 
 March 2022      Limited                 Life science          GBP50,000           11.2%             25.4% 
=============  =======================  ==============  ================  ==============  ================ 
                Censo Biotechnologies    Pharma 
 March 2022      Ltd                      Services            GBP400,000            3.7%             17.2% 
=============  =======================  ==============  ================  ==============  ================ 
 June 2022      Rota Geek Limited        Technology           GBP750,000            2.4%              6.7% 
=============  =======================  ==============  ================  ==============  ================ 
 August 2022    Thanksbox Limited        Technology           GBP400,000            4.7%             12.9% 
=============  =======================  ==============  ================  ==============  ================ 
 

We believe the portfolio is well positioned to continue to provide long term growth to shareholders and that our Investment Manager is similarly positioned to exploit these opportunities.

Further information can be found on new investee companies Destiny Pharma PLC, Riff Raff Entertainment Limited, Notify Technology Limited and Optalitix Limited in the Investment Manager's Report.

Buybacks

During the period, the Company bought back and cancelled 846,270 Ordinary shares. The Company continues to review opportunities to carry out share buybacks at a discount of no greater than 5% to NAV.

Dividends

As mentioned above, a dividend was paid on 31 July 2022 of 3.06 pence per eligible Ordinary share.

Board composition

The board consist of four Directors, three of which are independent from the Manager.

Ordinary share issue

The offer for subscription for Ordinary Shares that opened on 13 September 2021 and closed on 26 August 2022 received aggregate subscriptions from the issue of Ordinary shares of GBP6.7 million. On 21 September 2022 a new prospectus was launched for a further offer for subscription for Ordinary Shares, with the shares to be issued in the 2022/23 and 2023/24 tax years.

I invested GBP5,000 under the offer that closed in August 2022 and had 7,077 shares allotted in June 2022. These shares were acquired on the same terms as the shares subscribed for by other investors in the offer.

Developments since the period end

As mentioned above. since the period end the Company has made a follow on investment of GBP300,000 in Wazoku to support the development of its software.

Future prospects

It is generally accepted that the UK is heading towards more challenging markets however the Board is optimistic that the portfolio's predominant exposure to B2B technology, healthcare, life sciences and entertainment sectors will mean the Company is shielded to some extent. Your Board continues to keep a watchful brief over developments and our Investment Manager is working closely with our portfolio companies. We maintain our cautious but optimistic outlook.

Jan Ward

Chairman, 18 October 2022

[1] Total return per share is a non-GAAP Alternative Performance Measure ("APM"). It is taken from the Income Statement on page 12 and is calculated by taking the total profit or loss for the period and dividing by the weighted average number of shares. This has been selected to provide better understanding of the Company's performance over the period on a per share basis.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DOCGPGPCUUPPGUR

(END) Dow Jones Newswires

October 18, 2022 06:46 ET (10:46 GMT)

1 Year Calculus Vct Chart

1 Year Calculus Vct Chart

1 Month Calculus Vct Chart

1 Month Calculus Vct Chart

Your Recent History

Delayed Upgrade Clock